ConforMIS (NASDAQ:CFMS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday.

According to Zacks, “ConforMIS, Inc. is a medical technology company which develops, manufacture and sells joint replacement implants. The Company’s iFit technology platform consists of iFit Design, iFit Printing and iFit Just-in-Time Delivery. It operates primarily in the United States, Germany and the United Kingdom. The Company serves orthopedic surgeons, hospitals and other medical facilities and patients. ConforMIS, Inc. is based in Bedford, United States. “

A number of other research analysts have also commented on CFMS. Canaccord Genuity cut their target price on ConforMIS from $5.00 to $4.00 and set a “hold” rating for the company in a research note on Thursday, February 8th. Oppenheimer set a $4.00 target price on ConforMIS and gave the company a “buy” rating in a research note on Thursday, February 8th. BTIG Research restated a “hold” rating on shares of ConforMIS in a research note on Thursday, November 2nd. Finally, JPMorgan Chase & Co. lowered ConforMIS from a “neutral” rating to an “underweight” rating in a research note on Tuesday, January 2nd. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company’s stock. ConforMIS presently has an average rating of “Hold” and a consensus price target of $4.88.

ConforMIS (NASDAQ:CFMS) opened at $1.46 on Monday. The company has a debt-to-equity ratio of 0.52, a current ratio of 6.19 and a quick ratio of 5.38. The company has a market capitalization of $66.13 and a price-to-earnings ratio of -1.18. ConforMIS has a 12 month low of $1.15 and a 12 month high of $8.61.

ConforMIS (NASDAQ:CFMS) last issued its earnings results on Wednesday, February 7th. The medical instruments supplier reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.03. The business had revenue of $20.80 million during the quarter, compared to analyst estimates of $20.07 million. ConforMIS had a negative return on equity of 78.44% and a negative net margin of 68.59%. ConforMIS’s revenue was down 4.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.37) earnings per share. research analysts predict that ConforMIS will post -0.86 EPS for the current fiscal year.

In other ConforMIS news, CEO Mark A. Augusti sold 16,548 shares of the stock in a transaction on Tuesday, December 19th. The stock was sold at an average price of $2.27, for a total transaction of $37,563.96. Following the completion of the transaction, the chief executive officer now directly owns 285,007 shares in the company, valued at $646,965.89. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 43,691 shares of company stock valued at $91,154 over the last quarter. Corporate insiders own 9.55% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in CFMS. Stonebridge Capital Management Inc. acquired a new position in ConforMIS during the third quarter worth $130,000. The Manufacturers Life Insurance Company raised its stake in ConforMIS by 21.4% during the second quarter. The Manufacturers Life Insurance Company now owns 37,121 shares of the medical instruments supplier’s stock worth $158,000 after acquiring an additional 6,535 shares in the last quarter. Alliancebernstein L.P. raised its stake in ConforMIS by 31.1% during the second quarter. Alliancebernstein L.P. now owns 40,000 shares of the medical instruments supplier’s stock worth $172,000 after acquiring an additional 9,500 shares in the last quarter. Rhumbline Advisers raised its stake in ConforMIS by 21.8% during the second quarter. Rhumbline Advisers now owns 44,782 shares of the medical instruments supplier’s stock worth $192,000 after acquiring an additional 8,017 shares in the last quarter. Finally, Swiss National Bank raised its stake in ConforMIS by 59.2% during the second quarter. Swiss National Bank now owns 53,500 shares of the medical instruments supplier’s stock worth $230,000 after acquiring an additional 19,900 shares in the last quarter. Hedge funds and other institutional investors own 26.99% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “ConforMIS (CFMS) Upgraded by Zacks Investment Research to Hold” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.watchlistnews.com/conformis-cfms-upgraded-by-zacks-investment-research-to-hold/1864329.html.

ConforMIS Company Profile

ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.

Get a free copy of the Zacks research report on ConforMIS (CFMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for ConforMIS (NASDAQ:CFMS)

Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.